Individualized Approach to the Management of Coronary Heart Disease. Identifying the Nonresponders Before It Is Too Late

Journal of the American College of Cardiology

Volumn 53, Issue 4, 2009, Pages 331-333

  Ganz, Peter ^a   Hsue, Priscilla Y ^a  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

coronary artery disease; endothelium; prognosis; risk factor

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; APOLIPOPROTEIN E; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC OXIDE; ROSUVASTATIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CORONARY RISK; DIABETES MELLITUS; DIET RESTRICTION; EDITORIAL; EXERCISE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INFLAMMATION; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; PHARMACOGENETICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR; SMOKING CESSATION; TREATMENT OUTCOME; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CORONARY DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PLATELET AGGREGATION INHIBITORS; TREATMENT OUTCOME;

EID: 58249089338     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.10.021     Document Type: Editorial

References (21)

1. Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
2. Giacomini K.M., Brett C.M., Altman R.B., et al. The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther 81 (2007) 328-345
3. Schwarz U.I., Ritchie M.D., Bradford Y., et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 358 (2008) 999-1008
4. Chasman D.I., Posada D., Subrahmanyan L., Cook N.R., Stanton Jr. V.P., and Ridker P.M. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 291 (2004) 2821-2827
5. Thompson J.F., Man M., Johnson K.J., et al. An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J 5 (2005) 352-358
6. Morrow D.A., de Lemos J.A., Sabatine M.S., et al. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation 114 (2006) 281-288
7. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 352 (2005) 29-38
8. Ridker P.M., Cannon C.P., Morrow D., et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352 (2005) 20-28
9. Kinlay S., Timms T., Clark M., et al. Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia. Am J Cardiol 89 (2002) 1205-1207
10. Ridker P.M. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 108 (2003) 2292-2297
11. Furchgott R.F., and Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288 (1980) 373-376
12. Ludmer P.L., Selwyn A.P., Shook T.L., et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 315 (1986) 1046-1051
13. Deanfield J.E., Halcox J.P., and Rabelink T.J. Endothelial function and dysfunction: testing and clinical relevance. Circulation 115 (2007) 1285-1295
14. Ganz P., and Vita J.A. Testing endothelial vasomotor function: nitric oxide, a multipotent molecule. Circulation 108 (2003) 2049-2053
15. Lerman A., and Zeiher A.M. Endothelial function: cardiac events. Circulation 111 (2005) 363-368
16. Benjamin E.J., Larson M.G., Keyes M.J., et al. Clinical correlates and heritability of flow-mediated dilation in the community: the Framingham Heart Study. Circulation 109 (2004) 613-619
17. Vita J.A., Treasure C.B., Nabel E.G., et al. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 81 (1990) 491-497
18. Yeboah J., Crouse J.R., Hsu F.C., Burke G.L., and Herrington D.M. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. Circulation 115 (2007) 2390-2397
19. Davis S.F., Yeung A.C., Meredith I.T., et al. Early endothelial dysfunction predicts the development of transplant coronary artery disease at 1 year posttransplant. Circulation 93 (1996) 457-462
20. Modena M.G., Bonetti L., Coppi F., Bursi F., and Rossi R. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J Am Coll Cardiol 40 (2002) 505-510
21. Kitta Y., Obata J.-e., Nakamura T., et al. Persistent impairment of endothelial vasomotor function has a negative impact on outcome in patients with coronary artery disease. J Am Coll Cardiol 53 (2009) 323-330